Aarkstore - Zogenix, Inc. (Zgnx) - Financial and Strategic Swot Analysis Review

Zogenix, Inc. (ZGNX) - Financial and Strategic SWOT Analysis Review

Browse Full Report @

http://www.aarkstore.com/medical-devices/68310/zogenix-inc-zgnx-financial-and-strategic-swot-analysis-review

Published: Mar. 2015| No. Of Pages: 25 Pages

Summary

Zogenix, Inc. (Zogenix) is a pharmaceutical company. The company develops and commercializes injectable therapies and delivery systems for the treatment of central nervous system disorders and pain. Its products include Zohydro ER, RELDAY, Sumavel DosePro and undisclosed dosepro CNS product candidate. Zogenix’s Zohydro ER is an opioid agonist of hydrocodone bitartrate used for the pain management. The company’s Sumavel DosePro is a needle-free delivery system to treat people with acute migraine or cluster headaches. It provides education materials about the therapeutic products for patients and physicians. The company partners with Battelle. Zogenix is headquartered in San Diego, California, the US.

Zogenix, Inc. Key Recent Developments

Feb 10, 2015: Zogenix Appoints Industry Veteran Renee Tannenbaum to Its Board of Directors

Jan 12, 2015: Zogenix Provides Business Update

Dec 20, 2013: Zogenix Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Dec 17, 2013: Zogenix Appoints Chief Medical Officer and Expands Medical Leadership Team

Dec 04, 2013: Zogenix to Present at the Oppenheimer 24th Annual Healthcare Conference

This comprehensive SWOT profile of Zogenix, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over...